26.84
+4.27%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Elanco Animal Health
From its filings with the US Securities and Exchange Commission
Elanco Animal Health is based in Indianapolis, Indiana. Its shares trade on NYSE under the ticker ELAN. The SEC classifies its business as pharmaceutical preparations. In the fiscal year to 31 December 2025, it reported revenue of $4.71bn and a net loss of $232.0m. At that date it held total assets of $13.36bn and shareholders' equity of $6.55bn. By business, Farm Animal: brought in 50.1% of revenue, followed by Pet Health at 48.8% and Contract Manufacturing and Other at 1.1%. By region, International accounted for 52.6%, followed by United States at 47.4%.
Elanco Animal Health Incorporated and its subsidiaries (collectively, Elanco, the Company, we, us, or our) is a global leader in animal health, dedicated to innovating and delivering products and services to prevent and treat disease in farm animals and pets. We partner with farmers, pet owners, veterinarians and society to create value and help our customers improve the health of animals in their care, while also making a meaningful impact on the communities we serve. Our diverse, durable product portfolio is sold in more than 90 countries and serves animals across many species, primarily: dogs and cats (collectively, pet health) and cattle, poultry, swine and sheep (collectively, farm animal). Our purpose – making life better for animals makes life better – inspires us to Go Beyond for animals, our customers, our people and society.
Go Beyond for Animals – Our strong portfolio, high-impact innovation, unique market approach and dedication to making life better allow us to go beyond for animals to address critical health needs and increase access to health products and services.
Go Beyond for Customers – Our ability to reach the world's animals, along with our customer promise, to advocate, earn trust and solve big challenges to create value, allows us to go beyond for our customers, unlocking economic value for producers through science-based, scalable and sustainable solutions and supporting the professional wellness of veterinarians.
Quoted from its 10-K, filed 24 Feb 2026. Read the filing on SEC.gov ↗
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 20 Sept 2018
- Employees
- 9,400
- Website
- elanco.com ↗
- Head office
- 450 ELANCO CIRCLE, INDIANAPOLIS, IN, 46221
- Classification
- Pharmaceutical Preparations
- Filer status
- Large accelerated filer
Leadership
Pay as last reported
- Mr. Lawrence KurziusIndependent Chairman of the Board$426,083
- Mr. Jeffrey SimmonsPresident, Chief Executive Officer, Director, since 2018$14.8m
- Mr. Robert VanhimbergenExecutive Vice President, Chief Financial Officer
- Mr. Todd YoungChief Financial Officer, Executive Vice President$4.1m
- Ms. Shiv O'NeillExecutive Vice President, General Counsel, Corporate Secretary
- Mr. David KinardExecutive Vice President - Human Resources, Corporate Communications and Administration$2.9m
- Mr. Timothy BettingtonExecutive Vice President - Corporate Strategy and Market Development$2.5m
- Dr. Ramiro CabralExecutive Vice President; President of Elanco International$2.9m
- Dr. Ellen de BrabanderExecutive Vice President - Innovation and Regulatory Affairs$3.9m
- Ms. Grace McardleExecutive Vice President - Manufacturing and Quality
- Mr. Rajeev ModiExecutive Vice President - U.S. Pet Health and Global Digital Transformation$2.2m
- Dr. Jose Manuel SimasExecutive Vice President - U.S. Farm Animal Business
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 68
- Environment
- 63
- Social
- 82
- Governance
- 60
- Direct emissions (scope 1)
- 112,250 t
- Energy emissions (scope 2)
- 197,833 t
- Value chain emissions (scope 3)
- 655,353 t
- Women in the workforce
- 46.24872%
- Carbon reduction policy
- Yes
- Human rights policy
- Yes
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Elanco Animal Health Inc has established itself as a leading company in the animal health industry, known for its expertise and innovation.
- The company offers a diverse portfolio of products and services catering to various animal species, providing a strong foundation for growth.
- Elanco has a wide distribution network and strong relationships with veterinarians and other suppliers, enabling efficient delivery of its products and facilitating customer satisfaction.
Weaknesses
- One weakness of Elanco Animal Health Inc is its dependence on a few key product lines, which may expose the company to risks if there are any issues with those products.
- The company also faces intense competition from other players in the animal health industry, which may impact its market share and profitability.
- Elanco's global presence is not as extensive as some of its competitors, limiting its reach in certain markets.
Opportunities
- The growing worldwide demand for animal protein presents a significant opportunity for Elanco to expand its product offerings and capture a larger market share.
- The increasing trend of pet ownership and humanization of pets provides an opportunity for the company to develop and market specialized products catering to this growing market segment.
- Expanding into emerging markets, where the demand for animal health products is rising, can further drive the company's growth and revenue.
Threats
- Regulatory changes and stricter compliance requirements in the animal health industry pose a threat to Elanco, as non-compliance may lead to legal and financial consequences.
- An economic downturn or recession can potentially impact consumer spending on animal health products, affecting the company's sales and profitability.
- The emergence of alternative therapies and treatments, such as naturopathy, may pose a threat to traditional pharmaceutical products offered by Elanco.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.